"Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so. The Food and Drug Administration (FDA) today authorized the restart in the US, following the resumption of trials in other countries in recent weeks. The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial. As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on 6 September to allow the examination of safety data by independent monitoring committees. The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume. It is not unusual that in large scale vaccine trials, some participants will become unwell, and every case has to be evaluated to ensure the careful assessment of safety. Results from the late-stage trials are anticipated later this year , depending on the rate of infection within the communities where the clinical trials are being conducted. Data readouts will be submitted to regulators and published in peer-reviewed scientific journals. Rolling reviews of the vaccine programme have already begun in countries where this regulatory pathway has been established, providing regulators access to data as soon as they become available" (see press release HERE ). See our AZN AmpCard to learn more. #AZN #AZD1222 #COVID19Vaccine #COVID #coronavirus #covidtherapeutic #covidtherapy #infectiousdisease
#CHRS "announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020 . Starting at 4:30 p.m. EST , Coherus’ management team will host a conference call to discuss financial results and provide a general business update" (see press release HERE ).
Conference Call Information When: Thursday, November 5, 2020 starting at 4:30 p.m. EST Webcast: https://investors.coherus.com Dial-in: 844-452-6826 (Toll-Free U.S. and Canada) or 765-507-2587 (International)
Please dial-in 15 minutes early to ensure a timely connection to the call. Conference ID: 7079429 Access webcast HERE . See our CHRS AmpCard to learn more. #CHRS, #UDENYCA, #pegfilgrastim-cbqv
#BCRX "announced that the company will report its third quarter 2020 financial results on Thursday, November 5, 2020.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 3766784. A live webcast of the call and any slides will be available online at the investors section of the company website at www. biocryst .com . A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 3766784" (see press release HERE ). Access webcast HERE . See our BCRX AmpCards HERE . #BCRX